RA Research, Resources, and Rheumatology Archives | Page 6 of 11 | Rheumatoid Arthritis Warrior

Preclinical Rheumatoid Disease: There Are No Joints in the Lungs

My mom used to read to me John Godfrey Saxe’s 19th century version of a famous Indian legend, The Blind Men and the Elephant. I’m certain it contributed to my zealous love of evidence. Over the last couple of years, interacting with thousands of people with Rheumatoid disease, I came to the conclusion that only...Continue reading      57 Comments » Read more

The Immune Fingerprint and Rheumatoid Disease

I’ve made up another term because I haven’t heard of anything suitable: “immune fingerprint.” It occurred to me that while we talk about how the disease Rheumatoid Arthritis (or Rheumatoid Autoimmune Disease) affects us, one key to understanding disease activity may be considering how we affect the disease. If a disease disrupts the immune system, causing...Continue reading      26 Comments » Read more

Are Biosimilars Justice in Competition for Biologics Like Enbrel?

The FDA definition of biosimilars and a pathway to approval Biosimilars are pharmaceuticals that are similar to biologics such as Enbrel and Humira, but not chemically identical as with generic drugs. If the unique molecules used to create a biologic (from living proteins) such as Enbrel are not cloned, but carefully imitated, they are considered “biosimilar.”...Continue reading      13 Comments » Read more

What Causes Rheumatoid Arthritis to Trigger?

What causes Rheumatoid Arthritis? (UPDATED) I never asked “why me?” when diagnosed with RA because it’s not my way of thinking. Yet people do ask me “HOW did this happen?” or “What triggers RA?” What causes rheumatoid arthritis - that's the multi-billion dollar question! Here’s a summary of what is known at this point. There are a...Continue reading      92 Comments » Read more

The HAQ’s, the RAPID’s & the Rest: 3 Reasons It’s a Moot Point

So often when I’m listening to a scientific presentation about clinical care for Rheumatoid Arthritis, I would do the face-palm head-smack, if my shoulder would let me. Depending on who can hear me, I mutter softly or wail sarcastically, “If it’s not done, does this matter?” One example is measuring RA disease activity, especially with...Continue reading      43 Comments » Read more

Pfizer’s JAK inhibitor Tofacitinib EMA Application Validated

Pfizer JAK-3 press release “Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis: Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by...Continue reading      10 Comments » Read more

Mayo Clinic Video Interview: Patients at ACR Scientific Meeting

Some of you may be puzzled about what I’m doing in Chicago. So here’s a brief summary and a video interview with Mayo Clinic News Blog telling why patients are interested in a scientific meeting like the ACR Scientific Meeting. What happens at the American College of Rheumatology Scientific Meeting? “The ACR/ARHP Annual Scientific Meeting will be...Continue reading      11 Comments » Read more

When Rheumatology Is Sexy

If medicine can be sexy the way a new car or an iPhone is, what about rheumatology? Is there anything desirable or exciting there? Possibly, according to rheumatologist Ronan Kavanagh who wrote “The sexiness and cool of rheumatology.” Mostly, rheumatologists examine things that healthy people look away from: disability, deformity, and pain. The father of modern...Continue reading      16 Comments » Read more

A Paradigm Shift in Rheumatoid Arthritis Disease Activity? Part 3

In Part 1, we pointed out that patients and clinicians look at Rheumatoid Arthritis disease activity in different ways. Rheumatologists especially focus on joints, and actually particular kinds of joint activity. Patients face much more with regard to disease activity, as reflected in the post and comments page. In Part 2, we looked at two specific...Continue reading      59 Comments » Read more

A Paradigm Shift in Rheumatoid Arthritis Disease Activity? Part 2

In part 1 of A Paradigm Shift in Rheumatoid Arthritis Disease Activity, we considered some reasons why better ways of considering RA disease activity are needed. Ideally, three key things should be considered regarding RA disease activity: The patient’s estimation of his disease activity (more here). Appropriate monitoring using available tests (read more here!) A more complete paradigm...Continue reading      28 Comments » Read more

RA News Headlines, Vol. 6: Ibuprofen for Pain, Orencia Shots, New RA test, RA Inflammation Increases CV Risk

4 Big Headlines for RA News 1) Ibuprofen beats acetaminophen & a combination of both in knee pain Thanks to Dr. Kirsch for Tweeting this fantastic editorial about an arthritis pain relief study in the Annals of Rheumatic Diseases last week. The column highlights data in a new long-term study of the two most popular over-the-counter pain...Continue reading      8 Comments » Read more

New Way to Report Response in RA Clinical Trials?

Untangling a possible replacement for the “familiar” ACR 20 describing treatment response in clinical trials for Rheumatoid Arthritis Special thanks to Jay Sprinkel for assistance with this post. Although he may be more known for the humor he provides to our Facebook group, Jay is a retired marine biologist who specializes in statistics. He is also...Continue reading      15 Comments » Read more
“imaware™

    Welcome to RA Warrior!

    Welcome

    Thanks for visiting this unique site full of information and encouragement to fight Rheumatoid Disease. You'll find hope, humor, and a helpful online community. I'm Kelly & I'll be glad to show you around if you'll click right here.

    Advertisement

    View more gifts at Zazzle.

    Let's Pin Together!

Would You Like Free Email Updates?
Stay in touch with RA Warrior.
We respect your privacy. Your email address will never be shared.